TITLE

Raloxifene reduces endometrial cancer risk

AUTHOR(S)
Elliott, William T.
PUB. DATE
November 2008
SOURCE
Travel Medicine Advisor;Nov2008 Pharmacology Watch, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses research on the link between raloxifene, a selective estrogen receptor modulator (SERM), and reduced risk of endometrial cancer. It references a study conducted by researchers from the University of Pennsylvania, published in a 2008 issue of the "Journal of Clinical Oncology." In the study, researchers compared endometrial cancer rates in women receiving raloxifene, tamoxifen and non-users of SERM. Researchers concluded that the raloxifene group had lower risk of developing endometrial cancer compared with tamoxifen users.
ACCESSION #
35130415

 

Related Articles

  • Lilly's Evista Builds Bone.  // Medical Update;Jul2002, Vol. 28 Issue 1, p2 

    Discusses the impact of Evista, a selective estrogen receptor modulator, on the development of osteoporosis.

  • Evista.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p818 

    An encyclopedia entry for "Evista," which refers to Raloxifene, is presented.

  • Osteoporosis Drug Reduces Breast Cancer Risk. Sizing, Matt // Life Extension;Dec2006, Vol. 12 Issue 12, p15 

    The article presents a study on the effectiveness of raloxifene,a drug used to prevent and treat osteoporosis, in reducing the risk for breast cancer in postmenopausal women. Scientists from the University of Michigan analyzed data from a four-year trial involving women and a four year follow up...

  • Breast cancer: The challenges facing surgeons in the next two decades. O'Higgins, N. // Surgeon (Edinburgh University Press);Jun2005, Vol. 3 Issue 3, p206 

    The article presents information about breast cancer. Recent studies in the field of primary prevention of breast cancer have proposed the use of tamoxifen and raloxifene. The effectiveness of tamoxifen in the prevention of breast cancer remains in doubt due to the varying results of the trials...

  • Raloxifene reduces endometrial cancer risk. Elliott, William T. // Primary Care Reports;Nov2008 Pharmacology Watch, p2 

    The article discusses the role of raloxifene in reducing the risk of endometrial cancer, based on a study by researchers from the University of Pennsylvania and published in the 2008 issue of the "Journal of Clinical Oncology." A comparison of endometrial cancer rates in women on raloxifene,...

  • Raloxifene reduces endometrial cancer risk.  // Neurology Alert;Nov2008 Pharmacology Watch, p2 

    The article discusses research on the link between raloxifene, a selective estrogen receptor modulator (SERM), and reduced risk of endometrial cancer. It references a study conducted by researchers from the University of Pennsylvania, published in a 2008 issue of the "Journal of Clinical...

  • Measuring estradiol identifies breast Ca risk in postmenopausal women. Cummings, S. R.; Duong, T.; Kenyon, E. // Contemporary OB/GYN;Jun2002, Vol. 47 Issue 6, p24 

    Reports on a placebo controlled trial that investigated the use of estradiol level measurement to identify postmenopausal women at high risk for breast cancer and might benefit from the selective estrogen receptor modulator raloxifene. Subjects and approach used in the study; Results of the...

  • Raloxifene. Kellen, John A. // Current Drug Targets;Dec2001, Vol. 2 Issue 4, p423 

    Efforts to interfere with the initiation and promotion of breast and other cancers by endocrine manipulation are not new. It is of obvious benefit to cancer patients to administer substances that combine minimal general toxicity with maximal oestrogen inhibition. Raloxifene is a relatively...

  • Novel agents in osteoporosis. Shah, H.D. // Indian Journal of Pharmacology;Feb2004, Vol. 36 Issue 1, p48 

    Discusses the different therapeutic agents for osteoporosis. Raloxifene; Strontium ranelate.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics